Inspire: Azasite doesn't meet goals in trials

North Carolina-based Inspire Pharmaceuticals announced this morning that Azasite, a drug already approved to treat conjunctivitis, failed to reach the main endpoint in two Phase II clinical trials evaluating it in blepharitis patients. The company says it will conduct additional work to refine trial parameters for an anticipated Phase III program. Inspire's release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.